Sign In
Buy INRLF
$2.74
+0.160 (+6.20%)
At Close: Jun 03, 2026
Valneva SE (VALN) Q4 2024 Earnings Call Transcript
08:00pm, Thursday, 20'th Mar 2025
Valneva SE (NASDAQ:VALN ) Q4 2024 Earnings Conference Call March 20, 2025 10:00 AM ET Company Participants Joshua Drumm – Vice President-Global Investor Relations Thomas Lingelbach – Chief Executi
Valneva Is A 'Buy' As A First-Mover In Chikungunya
03:48pm, Thursday, 23'rd Jan 2025
Valneva Is A 'Buy' As A First-Mover In Chikungunya
Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot
10:44am, Tuesday, 21'st Jan 2025
On Tuesday, Valneva SE VALN reported Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, Ixchiq.
Valneva SE (VALN) Q3 2024 Earnings Call Transcript
01:10pm, Saturday, 09'th Nov 2024
Valneva SE (NASDAQ:VALN ) Q3 2024 Earnings Conference Call November 7, 2024 9:00 AM ET Company Participants Thomas Lingelbach - Chief Executive Officer Peter Buhler - Chief Financial Officer Joshua Dr
Pfizer and Valneva report positive results in mid-stage trial of Lyme disease vaccine
06:50am, Tuesday, 03'rd Sep 2024
The Phase 2 trial was evaluating the vaccine called VLA15 following a second booster dose given one year after the first one.
EU regulator recommends use of Valneva's chikungunya vaccine
06:48am, Friday, 31'st May 2024
The European Medicines Agency (EMA) recommended the use of Valneva's single-shot vaccine for chikungunya virus, the regulator said on Friday.
Valneva SE (VALN) Q4 2023 Earnings Call Transcript
04:22pm, Wednesday, 20'th Mar 2024
Valneva SE (VALN) Q4 2023 Earnings Call Transcript
French biotech company Valneva raises product sales guidance
02:48am, Wednesday, 20'th Mar 2024
French biotech company Valneva on Wednesday raised its product sales guidance and said it now expects revenues of between 170 million euros and 190 million euros ($184.72 million to $206.45 million) i
Valneva sells chikungunya vaccine priority review voucher for $103 mln
01:20am, Monday, 05'th Feb 2024
French vaccine maker Valneva said on Monday it sold the priority review voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million.
Valneva says EU regulator accepts its chikungunya vaccine application
01:19am, Monday, 27'th Nov 2023
French drugmaker Valneva said on Monday that the application for its vaccine candidate against mosquito-borne viral disease chikungunya was accepted by the European Medicines Agency (EMA) which would
FDA approves Valneva's Chikungunya vaccine for adults
01:23am, Friday, 10'th Nov 2023
French drugmaker Valneva said on Friday the U.S. Food and Drug Administration (FDA) has approved its Chikungunya single-dose vaccine in individuals aged 18 and above.
US FDA approves Valneva's chikungunya vaccine
05:18pm, Thursday, 09'th Nov 2023
The U.S. Food and Drug Administration (FDA) on Thursday approved Valneva's single-shot vaccine for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus.
Valneva's Vaccination Valor: A Buy Rating Justified
11:45pm, Wednesday, 04'th Oct 2023
Valneva's 1H 2023 revenue declined compared to the previous year, but product sales more than doubled, driven by the recovery in the travel market. The phase 3 trial for VLA15, a Lyme disease vaccine
Valneva SE (VALN) Q2 2023 Earnings Call Transcript
01:06pm, Thursday, 21'st Sep 2023
Valneva SE (NASDAQ:VALN ) Q2 2023 Earnings Conference Call September 21, 2023 9:00 AM ET Company Participants Joshua Drumm - VP, IR Thomas Lingelbach - CEO Peter Buhler - CFO Conference Call Participa
Pfizer, Valneva announce 'positive' results for Lyme disease vaccine candidate booster shot
01:22am, Thursday, 07'th Sep 2023
Pfizer and French pharmaceutical peer Valneva announced on Thursday that a phase 2 study for its VLA15 Lyme disease vaccine candidate showed a "strong immune response" in both children and adolescents
